Nombre del producto:6-bromopyridin-2-amine

IUPAC Name:6-bromopyridin-2-amine

CAS:19798-81-3
Fórmula molecular:C5H5BrN2
Pureza:98%
Número de catálogo:CM101911
Peso molecular:173.01

Unidad de embalaje Stock disponible Precio($) Cantidad
CM101911-100g in stock NJǜ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :19798-81-3
Fórmula molecular:C5H5BrN2
Punto de fusión:-
Código de sonrisas:NC1=NC(Br)=CC=C1
Densidad:
Número de catálogo:CM101911
Peso molecular:173.01
Punto de ebullición:272.9°C at 760 mmHg
Nº Mdl:MFCD00137843
Almacenamiento:Keep in dark place, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.